Known CVD & T2D: See Access Info
MORE PATIENTS HAVE ACCESS TO JARDIANCE
than all DPP-4is or SGLT2is across Commercial and Medicare Part D*
Jardiance is not for treatment of type 1 diabetes or diabetic ketoacidosis.
*Source: Fingertip Formulary, health plan or state listed above, and/or data on file, Boehringer Ingelheim Pharmaceuticals, Inc. as of 8/1/2019. Placement on formulary does not establish clinical comparability of products, including safety and efficacy, and is not a guarantee of full or partial coverage and/or payment. Contact health plan, state, or www.medicare.gov for most current information, as it may change without notice. This is not intended to be an exhaustive list of all plans in your area. Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC do not sponsor or endorse any particular plan, and the company/plan names listed do not imply their endorsement of Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC, or the product(s) referenced.
Boehringer Ingelheim Pharmaceuticals, Inc. either owns or uses the trademark Jardiance® under license. Other referenced trademarks are owned by third parties.
†Percentage of covered lives represent a weighted average of both commercial and Part D availability.
‡Represents overall coverage.
ACC=American College of Cardiology; CV=cardiovascular; DPP-4i=Dipeptidyl Peptidase-4 Inhibitor; SGLT2i=Sodium-glucose Cotransporter 2 Inhibitors.
Reference: 1. Das SR, Everett BM, Birtcher KK, et al. 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Disease. J Am Coll Cardiol. Electronically published on November 26, 2018.